ライブ
FierceBiotechIndivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2FierceBiotechBMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecificEndpoints NewsWhat we heard at a health tech conference in BostonPromega BlogThe Filter You Didn’t ChooseFierceBiotechLabcorp raises full-year guidance, boosted by diagnostics, lab servicesFierceBiotechLeo Pharma pays $50M for Replay and its preclinical skin disease gene therapyEndpoints NewsCVS' healthcare delivery chief eyes potential in clinical AIPharmaVoicePfizer deals extend patent life for a top-selling rare disease drugFierceBiotechBeOne signs $2B deal for option on preclinical trispecific antibody from China’s HuahuiBioWorldMFDS clears Curocell’s anbal-cel as first homegrown CAR T therapyCytiva (Google News)Rockwell Automation and Cytiva launch Figurate SCADA system to eliminate digital bottlenecks in biopharmaceutical manufacturing - Manufacturing ChemistEndpoints NewsLack of specifics on obesity pill sales hover over Lilly’s first quarter
Endpoints News 2026年4月30日

The R&D 15: How pharma's top companies spent, won and lost on drug research

The R&D 15: How pharma's top companies spent, won and lost on drug research

原文
本文は利用できません。元の情報源をご確認ください。